誉衡药业：目前佩玛贝特片尚未在国内销售

Core Viewpoint - Yuheng Pharmaceutical (002437.SZ) is collaborating with Japan's Kowa Company to promote Pemabate Tablets, aimed at reducing triglyceride levels in adult patients with non-familial hypertriglyceridemia. The product is not yet available in the domestic market, but the company plans to initiate hospital entry and related development work next year based on market conditions [1]. Group 1 - Yuheng Pharmaceutical is involved in a partnership with Kowa Company for the promotion of Pemabate Tablets [1] - The primary indication for Pemabate Tablets is to lower triglyceride levels in adult patients with non-familial hypertriglyceridemia [1] - The product has not yet been launched in the domestic market [1] Group 2 - The company anticipates conducting hospital entry and development activities for the product next year [1] - The timing of these activities will depend on market conditions [1]